Clomipramine treatment of panic disorder: Pros and cons

Laszlo A. Papp, Franklin R. Schneier, Abby J. Fyer, Michael R. Liebowitz, Jack M. Gorman, Jeremy D. Coplan, Raphael Campeas, Brian A. Fallon, Donald F. Klein

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

Background: Controlled trials suggest that clomipramine may be a highly effective antipanic drug. Lowering the starting dose may alleviate troublesome initial side effects and increase acceptability and compliance. Method: Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment. Starting at 10 mg/day, the dose was gradually increased to a mean dose of 97 mg/day. Results: While completers showed highly significant improvement, the benefits were severely limited by a high dropout rate due to adverse reactions occurring mostly during the first 2 weeks of treatment. Conclusion: Given the alternatives, clomipramine should not be used as a first-line antipanic medication.

Original languageEnglish
Pages (from-to)423-425
Number of pages3
JournalJournal of Clinical Psychiatry
Volume58
Issue number10
DOIs
Publication statusPublished - 1997

ASJC Scopus Subject Areas

  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Clomipramine treatment of panic disorder: Pros and cons'. Together they form a unique fingerprint.

Cite this